Eisai

4523.TApproved

Tokyo, JapanFounded 1941eisai.com

Eisai is a Japanese pharmaceutical giant with a strong commitment to human health care (hhc), focusing on addressing unmet medical needs in neurology, oncology, and neglected tropical diseases. The company has achieved significant breakthroughs in Alzheimer's treatment with Lecanemab and maintains a robust oncology portfolio including multi-targeted kinase inhibitors. Eisai is also deeply committed to global health initiatives, providing treatments for neglected tropical diseases in developing countries while maintaining strong financial performance as a publicly traded company.

Market Cap

$8.4B

Founded

1941

Employees

10,000-15,000

Focus

Small Molecules

4523.T · Stock Price

USD 4764.001167.00 (-19.68%)

Historical price data

AI Company Overview

Technology Platform

Eisai operates a diversified pharmaceutical platform with expertise in neuroscience drug discovery, multi-targeted kinase inhibition, and HIF-2 alpha inhibition for oncology applications.

Pipeline Snapshot

773

773 drugs in pipeline, 165 in Phase 3

Drug	Indication	Stage
Adjunctive Zonisamide + Replacement with Zonisamide	Partial Seizures	Approved
zonisamide	Epilepsy	Approved
Fospropofol + Propofol/Lidocaine	Complication of Injection	Approved
donepezil hydrochloride (Aricept)	Vascular Dementia	Approved
perampanel	Epilepsy	Approved

FDA Approved Drugs

LEQEMBI IQLIKBLAAug 29, 2025

LEQEMBIBLAJan 6, 2023

DAYVIGONDADec 20, 2019

Opportunities

Eisai has significant growth opportunities through the expanding Alzheimer's treatment market with Lecanemab, combination oncology therapies showing positive Phase 3 results, and potential expansion into emerging markets through global health initiatives.

Risk Factors

Key risks include regulatory challenges as seen with recent product discontinuations, intense competition in both neurology and oncology markets, and operational complexities from global expansion including geopolitical risks affecting drug distribution.

Competitive Landscape

Eisai competes with major pharmaceutical companies including Biogen in Alzheimer's disease, and Pfizer, Bristol Myers Squibb in oncology. The company differentiates through innovative combination therapies and strong commitment to global health initiatives.

Publications

Patents

Pipeline

773

FDA Approvals